Subscribe (free) on Apple Podcasts, Google Podcasts, Android, RSS or by email.
Julie’s Biggest TakeawaysE. coli plays many roles inside and outside the scientific laboratory:
- Laboratory E. coli strains used by scientists to study molecular biology.
- Commensal E. coli strains contribute to digestion and health as part of the intestinal microbiome.
- Pathogenic E. coli strains have acquired factors that allow them to cause disease in people
The E. coli Shiga toxin (though not the bacterium itself) can pass through the epithelial cell layer to become systemic, and eventually the toxin will accumulate in the kidneys. This can lead to patients experiencing hemolytic uremic syndrome (HUS) and kidney failure, leading to lifelong dialysis or need for a transplant. An immune response that prevents the E. coli from attaching will prevent the bacterium from secreting toxin in close proximity to the epithelial cells and decrease likelihood of HUS development.
Burkholderia is a bacterial genus whose member species have been weaponized in the past, and which remain potent disease-causing agents around the world.
- B. mallei causes glanders, a disease mostly of horses and their handlers. It is a respiratory infection that can become systemic if not treated.
- B. pseudomallei causes melioidosis, a disease that can manifest in many ways. It is endemic in many tropical regions around the world, found in over 79 countries so far.
Coating gold nanoparticles with antigens against which the immune response will be protective is a method Alfredo has used for a number of candidate vaccines, including one against E. coli and one against B. pseudomallei. The nanoparticles can have the gold cleaved off to provide different functional variants of the same vaccine.
“E. coli O157:H7 is one of the most pathogenic E. coli because you need between 50-500 bacteria to get sick.”
“Within the big family of Enterobacteriaceae, there are several other members that are more prone to acquire antimicrobial resistant markers [than E. coli]: Klebsiella and several other organisms. We are reaching a point where all the antibiotics that we know are not working against some of these isolates. The alternative is to try to develop a vaccine that targets not one, but multiple components of the bacteria so there is less probability that the bacteria mutates to become resistant to that vaccine.”
“The way I think is to find the factors that allow the bacteria to become pathogenic.”
“One of the jobs at my institution is to be the Chief Diversity Officer. One thing I try to implement is small changes: I always say it’s with one faculty at a time that you can make a change. If we can do this, that one microbiologist can sponsor an underrepresented minority student and mentor them to become scientists, then we can have a grassroots movement.”
“You need to be passionate about what you do, because one thing that is complicated in science is how many times you’ll be told no. [Scientists] learn how to take those negative responses and try to make it a positive response.”
Links for This Episode
- MTM Listener Survey, only takes 3 minutes. Thanks!
- Alfredo Torres webpage at University of Texas Medical Branch
- McWilliams BD and Torres AG. Enterohemorrhagic Escherichia coli Adhesins. Microbiology Spectrum. 2013.
- Sanchez-Villamil JI et al. Development of a Gold Nanoparticle Vaccine against Enterohemorrhagic Escherichia coliO157:H7. mBio. 2019.
- Wiersinga WJ et al. Melioidosis. Nature Reviews Disease Primers. 2018.
- Khakhum N. et al. Evaluation of Burkholderia mallei ΔtonB Δhcp1 (CLH001) as a live attenuated vaccine in murine models of glanders and melioidosis. PLOS Neglected Tropical Diseases. 2019.
- Torres AG. Common Sense Can Keep You Safe in E. coli Outbreak. Galveston County Daily News. 2020.
- ABRCMS: Annual Biomedical Research Conference for Minority Students
- MTM: Burkholderia pseudomallei & the neglected tropical disease melioidosis with Direk Limmathurotsakul
- HOM Tidbit: Kiyoshi Shiga Biography in Clinical Infectious Diseases
History of Microbiology Tidbit
There are so many potential E. coli-related avenues to go down when discussing the history of microbiology! One could talk about the scientist for which the bacterium is named, the German bacteriologist Theodore von Escherich, or some of the numerous outbreaks, like the 2011 outbreak in Germany that Alfredo mentioned, or the 1993 Jack-in-the-Box outbreak – d you remember that? But for today’s history of microbiologist tidbit, we’ll cover the scientist for whom the toxin is named: Japanese bacteriologist Kiyoshi Shiga.
Shiga was born in 1871 in Sendai, in northern Japan. After starting medical school in 1892, he went to a lecture by Shibasburo Kitasato, another Japanese scientist and one whom had studied with prominent bacteriologist Robert Koch. After finishing his medical studies, Shiga became a research assistant at the Institute for Infectious Diseases which had been founded by Kitasato. In 1897, Shiga was told to begin studying a dysentery outbreak, which over the course of the outbreak would infect over 91,000 people and kill nearly 20,000. Dysentery at this time generally meant any violent case of diarrhea, and the Japanese word for the outbreak, sekiri, may be a better name. The word sekiri means “red diarrhea,” which more accurately describes the bowel movements accompanied by blood and mucus seen in shigellosis infections.
If you recognized the name Koch, you’re likely familiar with Koch’s postulates. These postulates are those by which a microbe is determined to be the cause of an infectious disease:
- First, the microorganism must be present in every case of disease.
- Second, the microorganism must be isolated from a disease host and grown in pure culture.
- Third, the disease must be recapitulated when a new host is infected with this pure culture.
- Fourth, the microorganism must be re-isolated from the infected host and shown to be the same as the original microbe.
So Shiga studied sekiri patients in order to perform the first of these. He isolated a Gram-negative bacillus that caused diarrhea when fed to dogs. But how could Shiga demonstrate that the re-isolated bacillus was the same as the one he had infected the dogs with, and not a contaminating microbe? There were no sequencing techniques or molecular tags to identify specific bacteria.
Shiga turned again to the dysentery patients, looking at their serum. Serum antibodies from the patients would bind the purified bacteria together, allowing a bacterial clump to precipitate out of solution. Of course, this was before antibodies were well characterized, but the immune sera were known to contain various components that would react against microbes which had previously caused disease. When patient sera was applied to the bacterial isolates from the sickened dogs, the same precipitation even occurred, indicating that the sera recognized the same bacteria they had previously seen in the patients. This was the confirmation Shiga needed in order to complete Koch’s postulates.
The bacterium identified was given the genus name Shigella, after its discoverer. Incidentally, this name was bestowed much later by bacterial taxonomists in the 1930s, as Shiga himself called it Bacillus dysenterie because of the bacterial shape. Shiga went on to describe the toxic factors that allowed the bacterium to cause disease, including Shiga toxin.
How did Shiga toxin from Shigella make their way into the Shiga toxigenic E. coli we discussed today? Some evidence exists that this gene was carried by a bacteriophage, which must have been a somewhat broad phage as it would have been generated from a Shigella bacterium and infected an Escherichia bacterium. These 2 bacteria are very similar—many scientists refer to them as cousins—but classically differ in other characteristics like motility and metabolic ability as well
Let us know what you thought about this episode by tweeting at us @ASMicrobiology or leaving a comment on facebook.com/asmfan.
Send your stories about our guests and/or your comments to firstname.lastname@example.org.